August 7th 2024
Why is it important for organizations to set long-term goals when planning for a sustainable future?
July 24th 2024
A deep dive into why this therapy has demonstrated effectiveness in various areas, including for tumors.
July 17th 2024
How teamwork among safety-net healthcare providers and pharma can make the difference.
June 7th 2024
Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.
May 30th 2024
These advancements continue to act as a key driver in helping to boost the security, efficiency, and innovation of global industries, include pharma.
Consultant pharmacists and long-term care 101
Resources for education about senior citizens and long-term care
Shifting healthcare dynamics needn’t be a bitter pill
The medical crisis that didn’t happen
Patient access strategy: specialty pharmacy, hub—or both?
Do you need to hire a hub service for your Patient Access Strategy or can you get by with a good specialty pharmacy
Since 1841: The Story of an Enduring Family Business
Morris & Dickson publishes a family and company history
Specialty drug market access reality check
Ten payer pressures to act on now
Enough already with REMS abuse in generic drug development
The keys to a successful and impactful partnership: A case study
Dealing with biologics production uncertainty
The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand
Serialization’s interface between the plant floor, the enterprise and the world
Dispense As Written
Laying the foundation for a national system for evidence generation
Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis
Strengthening healthcare and pharmaceutical supply chains is critical for healthcare resiliency
Specialty pharma becomes 'hub enabled'
Bringing value to healthcare: practical steps for getting to a market-based model
A new, market-driven model of drug development and commercialization is appearing*
A case study in differing approaches to reimbursement approval in Europe and the US
Looking at 'cost' and 'value' under different evaluation processes
Pharma logistics--so what?
Looking at the essential value of well-managed supply chains
Collaboration key to a healthy supply chain in 2016
HDMA seeks to encourage more outreach to business partners and government
Pharma's bread and butter is still made with powder
Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay
For better patient data in pharma, think CUPID
A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets
GDUFA Fee Relief For Small Businesses
Fees paid to FDA by small generic manufacturers are financially 'unfair'
Drug pricing will be a hot-button issue in this election cycle
Ten integrated imperatives for pharma commercial transformation
The pharma industry needs to go farther in adapting to new marketplace realities
Amarin Pharma v. U.S. Food and Drug Administration: Excerpts
The Phase III pricing experiment
Forecasting for the Pharmaceutical Industry
The second edition of an essential business planner's library
Does healthcare benefit from a unified approach to item-level serialization and UDI?
"If we had asked them, they would have asked for faster horses." ~ Henry Ford
Understanding the companion-diagnostics environment
While the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model
HPCLC Spring Meeting recap
Logistics managers in life sciences and personal care focus on transportation capacity
Pharmaceutical Commerce at 10
Politics and drugs
Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions